Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.

about

Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.

Item

http://www.wikidata.org/entity/Q54005515

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Eligibility for shorter treatm ...... culosis in the European Union.

@en

Eligibility for shorter treatm ...... culosis in the European Union.

@nl

type

Item

label

Eligibility for shorter treatm ...... culosis in the European Union.

@en

Eligibility for shorter treatm ...... culosis in the European Union.

@nl

prefLabel

Eligibility for shorter treatm ...... culosis in the European Union.

@en

Eligibility for shorter treatm ...... culosis in the European Union.

@nl

P1476

Eligibility for shorter treatm ...... rculosis in the European Union

@en

P2093

Marieke J van der Werf

http://www.w3.org/2001/XMLSchema#string

Masoud Dara

http://www.w3.org/2001/XMLSchema#string

Mike Catchpole

http://www.w3.org/2001/XMLSchema#string

Vahur Hollo

http://www.w3.org/2001/XMLSchema#string

P2860

Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials

Q28087469

Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.

High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene.

Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.

Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.

Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis.

WHO recommendations on shorter treatment of multidrug-resistant tuberculosis.

High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.

High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses.

P31

scholarly article

P356

10.1183/13993003.01992-2016

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

C Ködmön

P577

2017-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28331041

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance

P932

5898943

http://www.w3.org/2001/XMLSchema#string